Skip to main content
Top
Published in: Virology Journal 1/2023

Open Access 01-12-2023 | Human Papillomavirus | Research

Human papillomavirus infections among women with cervical lesions and cervical cancer in Yueyang, China: a cross-sectional study of 3674 women from 2019 to 2022

Authors: Min Zeng, Xiaoyun Zhang, LiLi He, Xin Liu, Huawen Liu, Rui Deng, Bo Qiu, Fang Liu, Hang Xiao, Quanlv Li, Wen Li, Chongmei Liu, Yangqing Ge

Published in: Virology Journal | Issue 1/2023

Login to get access

Abstract

Purpose

To investigate the distribution of the incidence and genotypes of human papillomavirus (HPV) among women with cervical cancer (CC) and precancerous cervical lesions in Yueyang City, China, to develop prevention and control strategies for CC.

Methods

A total of 3674 patients with cervical lesions and cervical cancer who attended 7 hospitals in Yueyang City between September 2019 and September 2022 were included. They included 1910 cervical intraepithelial neoplasia (CIN) I, 718 CIN II, 576 CIN II and 470 CC, respectively. The HPV genotyping of the above patients was detected by Real time-PCR in the laboratory department of each hospital.

Results

The total HPV prevalence was 74.69% (95% CI 73.28–76.09%) in 3674 patients. The incidence of high- and low-risk HPV was 73.46% and 7.21%, respectively. The prevalence of HPV in CIN I, CIN II, CIN III, and invasive CC (ICC) groups was 66.65% (1273/1910, 95% CI 64.53–68.77%), 80.78% (580/718, 95% CI 77.89–83.67%), 83.88% (483/576, 95% CI 80.84–86.87%), and 86.81% (408/470, 95% CI 83.74–89.88%), respectively. The top three HPV subtypes in ICC are HPV16, HPV52, and HPV58. The prevalence of HPV 16 increased with increasing disease severity, with this genotype being present in 12.57%, 20.89%, 36.98%, and 50.85% of CIN I, CIN II, CIN III, and ICC cases, respectively (p < 0.001). Single HPV infection was predominant in cervical lesions, with a prevalence of 48.50% (95% CI 46.89–50.12%). The HPV prevalence varied by age, being highest among women with ICC, CIN I, CIN II and CIN III aged ≥ 60 years, 50–59 years, 40–49 years, and 40–49 years, respectively.

Conclusion

The prevalence of HPV in patients with cervical lesions in Yueyang City was very high, with HPV 16, 52, 58, 53, and 51 being the five most common HPV genotypes in patients with cervical lesions.
Literature
1.
go back to reference Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.CrossRefPubMed Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.CrossRefPubMed
3.
go back to reference Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol. 2005;32(Suppl 1):S16-24.CrossRefPubMed Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol. 2005;32(Suppl 1):S16-24.CrossRefPubMed
4.
go back to reference Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ. International Agency for Research on Cancer Multicenter Cervical Cancer Study G: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518–27.CrossRefPubMed Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ. International Agency for Research on Cancer Multicenter Cervical Cancer Study G: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518–27.CrossRefPubMed
5.
go back to reference Trottier H, Franco EL. Human papillomavirus and cervical cancer: burden of illness and basis for prevention. Am J Manag Care. 2006;12(17 Suppl):S462-472.PubMed Trottier H, Franco EL. Human papillomavirus and cervical cancer: burden of illness and basis for prevention. Am J Manag Care. 2006;12(17 Suppl):S462-472.PubMed
6.
go back to reference Bernard HU, Burk RD, Chen Z, van Doorslaer K. zur Hausen H, de Villiers EM: classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology. 2010;401(1):70–9.CrossRefPubMed Bernard HU, Burk RD, Chen Z, van Doorslaer K. zur Hausen H, de Villiers EM: classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology. 2010;401(1):70–9.CrossRefPubMed
7.
go back to reference Pierce Campbell CM, Menezes LJ, Paskett ED, Giuliano AR. Prevention of invasive cervical cancer in the United States: past, present, and future. Cancer Epidemiol Biomarkers Prev. 2012;21(9):1402–8.CrossRefPubMedPubMedCentral Pierce Campbell CM, Menezes LJ, Paskett ED, Giuliano AR. Prevention of invasive cervical cancer in the United States: past, present, and future. Cancer Epidemiol Biomarkers Prev. 2012;21(9):1402–8.CrossRefPubMedPubMedCentral
8.
go back to reference Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human papillomavirus and cervical cancer. Lancet. 2013;382(9895):889–99.CrossRefPubMed Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human papillomavirus and cervical cancer. Lancet. 2013;382(9895):889–99.CrossRefPubMed
9.
go back to reference Zeng Z, Yang H, Li Z, He X, Griffith CC, Chen X, Guo X, Zheng B, Wu S, Zhao C. Prevalence and genotype distribution of hpv infection in China: analysis of 51,345 HPV genotyping results from China’s largest CAP certified laboratory. J Cancer. 2016;7(9):1037–43.CrossRefPubMedPubMedCentral Zeng Z, Yang H, Li Z, He X, Griffith CC, Chen X, Guo X, Zheng B, Wu S, Zhao C. Prevalence and genotype distribution of hpv infection in China: analysis of 51,345 HPV genotyping results from China’s largest CAP certified laboratory. J Cancer. 2016;7(9):1037–43.CrossRefPubMedPubMedCentral
10.
go back to reference Huh WK, Joura EA, Giuliano AR, Iversen OE, de Andrade RP, Ault KA, Bartholomew D, Cestero RM, Fedrizzi EN, Hirschberg AL, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial. Lancet. 2017;390(10108):2143–59.CrossRefPubMed Huh WK, Joura EA, Giuliano AR, Iversen OE, de Andrade RP, Ault KA, Bartholomew D, Cestero RM, Fedrizzi EN, Hirschberg AL, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial. Lancet. 2017;390(10108):2143–59.CrossRefPubMed
11.
go back to reference Kavanagh K, Pollock KG, Cuschieri K, Palmer T, Cameron RL, Watt C, Bhatia R, Moore C, Cubie H, Cruickshank M, et al. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. Lancet Infect Dis. 2017;17(12):1293–302.CrossRefPubMed Kavanagh K, Pollock KG, Cuschieri K, Palmer T, Cameron RL, Watt C, Bhatia R, Moore C, Cubie H, Cruickshank M, et al. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. Lancet Infect Dis. 2017;17(12):1293–302.CrossRefPubMed
12.
go back to reference Wang J, Tang D, Wang K, Wang J, Zhang Z, Chen Y, Zhang X, Ma C. HPV genotype prevalence and distribution during 2009–2018 in Xinjiang, China: baseline surveys prior to mass HPV vaccination. BMC Womens Health. 2019;19(1):90.CrossRefPubMedPubMedCentral Wang J, Tang D, Wang K, Wang J, Zhang Z, Chen Y, Zhang X, Ma C. HPV genotype prevalence and distribution during 2009–2018 in Xinjiang, China: baseline surveys prior to mass HPV vaccination. BMC Womens Health. 2019;19(1):90.CrossRefPubMedPubMedCentral
13.
go back to reference Zhang M, Zhong Y, Wang L, Bao H, Huang Z, Zhao Z, Zhang X, Li C, Sun KL, Wu J, et al. Cervical Cancer Screening Coverage - China, 2018–2019. China CDC Wkly. 2022;4(48):1077–82.CrossRefPubMedPubMedCentral Zhang M, Zhong Y, Wang L, Bao H, Huang Z, Zhao Z, Zhang X, Li C, Sun KL, Wu J, et al. Cervical Cancer Screening Coverage - China, 2018–2019. China CDC Wkly. 2022;4(48):1077–82.CrossRefPubMedPubMedCentral
14.
go back to reference Bao HL, Jin C, Wang S, Song Y, Xu ZY, Yan XJ, Li LM, Ning Y, Wang HJ. Prevalence of cervicovaginal human papillomavirus infection and genotypes in the pre-vaccine era in China: a nationwide population-based study. J Infect. 2021;82(4):75–83.CrossRefPubMed Bao HL, Jin C, Wang S, Song Y, Xu ZY, Yan XJ, Li LM, Ning Y, Wang HJ. Prevalence of cervicovaginal human papillomavirus infection and genotypes in the pre-vaccine era in China: a nationwide population-based study. J Infect. 2021;82(4):75–83.CrossRefPubMed
15.
go back to reference Hou J, Zeng M, Liu C, Xie B, Li Y, Wu L, Zhu L, Li M, Zhang Z, Zhang X, et al. Cervical HPV infection in Yueyang, China: a cross-sectional study of 125,604 women from 2019 to 2022. Front Public Health. 2023;11:1210253.CrossRefPubMedPubMedCentral Hou J, Zeng M, Liu C, Xie B, Li Y, Wu L, Zhu L, Li M, Zhang Z, Zhang X, et al. Cervical HPV infection in Yueyang, China: a cross-sectional study of 125,604 women from 2019 to 2022. Front Public Health. 2023;11:1210253.CrossRefPubMedPubMedCentral
16.
go back to reference Zhao FH, Lewkowitz AK, Hu SY, Chen F, Li LY, Zhang QM, Wu RF, Li CQ, Wei LH, Xu AD, et al. Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China: a pooled analysis of 17 population-based studies. Int J Cancer. 2012;131(12):2929–38.CrossRefPubMedPubMedCentral Zhao FH, Lewkowitz AK, Hu SY, Chen F, Li LY, Zhang QM, Wu RF, Li CQ, Wei LH, Xu AD, et al. Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China: a pooled analysis of 17 population-based studies. Int J Cancer. 2012;131(12):2929–38.CrossRefPubMedPubMedCentral
17.
go back to reference Ma X, Wang Q, Ong JJ, Fairley CK, Su S, Peng P, Jing J, Wang L, Soe NN, Cheng F, et al. Prevalence of human papillomavirus by geographical regions, sexual orientation and HIV status in China: a systematic review and meta-analysis. Sex Transm Infect. 2018;94(6):434–42.CrossRefPubMed Ma X, Wang Q, Ong JJ, Fairley CK, Su S, Peng P, Jing J, Wang L, Soe NN, Cheng F, et al. Prevalence of human papillomavirus by geographical regions, sexual orientation and HIV status in China: a systematic review and meta-analysis. Sex Transm Infect. 2018;94(6):434–42.CrossRefPubMed
18.
19.
go back to reference Jin R, Yang X, Bao J, Zhang W, Dou R, Yuan D, Yang Q, Jiang L, Yu H. The prevalence and genotype distribution of human papilloma virus in cervical squamous intraepithelial lesion and squamous cell carcinoma in Taizhou, China. Medicine. 2021;100(28):e26593.CrossRefPubMedPubMedCentral Jin R, Yang X, Bao J, Zhang W, Dou R, Yuan D, Yang Q, Jiang L, Yu H. The prevalence and genotype distribution of human papilloma virus in cervical squamous intraepithelial lesion and squamous cell carcinoma in Taizhou, China. Medicine. 2021;100(28):e26593.CrossRefPubMedPubMedCentral
21.
go back to reference Yan X, Shen L, Xiao Y, Wang Q, Li F, Qian Y. Prevalence, characteristics, and distribution of HPV genotypes in women from Zhejiang Province, 2016–2020. Virol J. 2021;18(1):208.CrossRefPubMedPubMedCentral Yan X, Shen L, Xiao Y, Wang Q, Li F, Qian Y. Prevalence, characteristics, and distribution of HPV genotypes in women from Zhejiang Province, 2016–2020. Virol J. 2021;18(1):208.CrossRefPubMedPubMedCentral
22.
go back to reference Zhang C, Zhang C, Huang J, Wu Z, Mei X, Shi W. Prevalence and genotype distribution of human papillomavirus among females in the suburb of Shanghai. China J Med Virol. 2018;90(1):157–64.CrossRefPubMed Zhang C, Zhang C, Huang J, Wu Z, Mei X, Shi W. Prevalence and genotype distribution of human papillomavirus among females in the suburb of Shanghai. China J Med Virol. 2018;90(1):157–64.CrossRefPubMed
23.
go back to reference Li K, Li Q, Song L, Wang D, Yin R. The distribution and prevalence of human papillomavirus in women in mainland China. Cancer. 2019;125(7):1030–7.CrossRefPubMed Li K, Li Q, Song L, Wang D, Yin R. The distribution and prevalence of human papillomavirus in women in mainland China. Cancer. 2019;125(7):1030–7.CrossRefPubMed
24.
go back to reference Zhang L, Bi Q, Deng H, Xu J, Chen J, Zhang M, Mu X. Human papillomavirus infections among women with cervical lesions and cervical cancer in Eastern China: genotype-specific prevalence and attribution. BMC Infect Dis. 2017;17(1):107.CrossRefPubMedPubMedCentral Zhang L, Bi Q, Deng H, Xu J, Chen J, Zhang M, Mu X. Human papillomavirus infections among women with cervical lesions and cervical cancer in Eastern China: genotype-specific prevalence and attribution. BMC Infect Dis. 2017;17(1):107.CrossRefPubMedPubMedCentral
25.
go back to reference Li J, Gao JJ, Li N, Wang YW. Distribution of human papillomavirus genotypes in western China and their association with cervical cancer and precancerous lesions. Arch Virol. 2021;166(3):853–62.CrossRefPubMed Li J, Gao JJ, Li N, Wang YW. Distribution of human papillomavirus genotypes in western China and their association with cervical cancer and precancerous lesions. Arch Virol. 2021;166(3):853–62.CrossRefPubMed
26.
go back to reference Azuma Y, Kusumoto-Matsuo R, Takeuchi F, Uenoyama A, Kondo K, Tsunoda H, Nagasaka K, Kawana K, Morisada T, Iwata T, et al. Human papillomavirus genotype distribution in cervical intraepithelial neoplasia grade 2/3 and invasive cervical cancer in Japanese women. Jpn J Clin Oncol. 2014;44(10):910–7.CrossRefPubMed Azuma Y, Kusumoto-Matsuo R, Takeuchi F, Uenoyama A, Kondo K, Tsunoda H, Nagasaka K, Kawana K, Morisada T, Iwata T, et al. Human papillomavirus genotype distribution in cervical intraepithelial neoplasia grade 2/3 and invasive cervical cancer in Japanese women. Jpn J Clin Oncol. 2014;44(10):910–7.CrossRefPubMed
27.
go back to reference de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048–56.CrossRefPubMed de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048–56.CrossRefPubMed
28.
go back to reference Li K, Yin R, Wang D, Li Q. Human papillomavirus subtypes distribution among 2309 cervical cancer patients in West China. Oncotarget. 2017;8(17):28502–9.CrossRefPubMedPubMedCentral Li K, Yin R, Wang D, Li Q. Human papillomavirus subtypes distribution among 2309 cervical cancer patients in West China. Oncotarget. 2017;8(17):28502–9.CrossRefPubMedPubMedCentral
29.
go back to reference Ma L, Lei J, Ma L, Cong X, Wang N, Yang H, Liu Q, Yu Y, Cao Y. Characteristics of women infected with human papillomavirus in a tertiary hospital in Beijing China, 2014–2018. BMC Infect Dis. 2019;19(1):670.CrossRefPubMedPubMedCentral Ma L, Lei J, Ma L, Cong X, Wang N, Yang H, Liu Q, Yu Y, Cao Y. Characteristics of women infected with human papillomavirus in a tertiary hospital in Beijing China, 2014–2018. BMC Infect Dis. 2019;19(1):670.CrossRefPubMedPubMedCentral
30.
go back to reference Zhao FH, Zhu FC, Chen W, Li J, Hu YM, Hong Y, Zhang YJ, Pan QJ, Zhu JH, Zhang X, et al. Baseline prevalence and type distribution of human papillomavirus in healthy Chinese women aged 18–25 years enrolled in a clinical trial. Int J Cancer. 2014;135(11):2604–11.CrossRefPubMedPubMedCentral Zhao FH, Zhu FC, Chen W, Li J, Hu YM, Hong Y, Zhang YJ, Pan QJ, Zhu JH, Zhang X, et al. Baseline prevalence and type distribution of human papillomavirus in healthy Chinese women aged 18–25 years enrolled in a clinical trial. Int J Cancer. 2014;135(11):2604–11.CrossRefPubMedPubMedCentral
31.
go back to reference Luo G, Sun X, Li M, Liu T, Hu G, He Y, Mao L, Yan L, Xie L, Zou H, et al. Cervical human papillomavirus among women in Guangdong, China 2008–2017: implication for screening and vaccination. J Med Virol. 2019;91(10):1856–65.CrossRefPubMed Luo G, Sun X, Li M, Liu T, Hu G, He Y, Mao L, Yan L, Xie L, Zou H, et al. Cervical human papillomavirus among women in Guangdong, China 2008–2017: implication for screening and vaccination. J Med Virol. 2019;91(10):1856–65.CrossRefPubMed
32.
go back to reference Long W, Yang Z, Li X, Chen M, Liu J, Zhang Y, Sun X. HPV-16, HPV-58, and HPV-33 are the most carcinogenic HPV genotypes in Southwestern China and their viral loads are associated with severity of premalignant lesions in the cervix. Virol J. 2018;15(1):94.CrossRefPubMedPubMedCentral Long W, Yang Z, Li X, Chen M, Liu J, Zhang Y, Sun X. HPV-16, HPV-58, and HPV-33 are the most carcinogenic HPV genotypes in Southwestern China and their viral loads are associated with severity of premalignant lesions in the cervix. Virol J. 2018;15(1):94.CrossRefPubMedPubMedCentral
33.
go back to reference Tang Y, Zheng L, Yang S, Li B, Su H, Zhang LP. Epidemiology and genotype distribution of human papillomavirus (HPV) in Southwest China: a cross-sectional five years study in non-vaccinated women. Virol J. 2017;14(1):84.CrossRefPubMedPubMedCentral Tang Y, Zheng L, Yang S, Li B, Su H, Zhang LP. Epidemiology and genotype distribution of human papillomavirus (HPV) in Southwest China: a cross-sectional five years study in non-vaccinated women. Virol J. 2017;14(1):84.CrossRefPubMedPubMedCentral
34.
go back to reference Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, de Sanjose S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010;202(12):1789–99.CrossRefPubMed Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, de Sanjose S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010;202(12):1789–99.CrossRefPubMed
35.
go back to reference de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664–70.CrossRefPubMedPubMedCentral de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664–70.CrossRefPubMedPubMedCentral
36.
go back to reference Bulk S, Berkhof J, Bulkmans NW, Zielinski GD, Rozendaal L, van Kemenade FJ, Snijders PJ, Meijer CJ. Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands. Br J Cancer. 2006;94(1):171–5.CrossRefPubMed Bulk S, Berkhof J, Bulkmans NW, Zielinski GD, Rozendaal L, van Kemenade FJ, Snijders PJ, Meijer CJ. Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands. Br J Cancer. 2006;94(1):171–5.CrossRefPubMed
37.
go back to reference Gong P, Wang Z, Geng J, Tan X. Comparative study on detection and typing of human papillomavirus (HPV) infection with microarray using paraffin-embedded specimens from squamous cell carcinoma and cervical precursor lesions. J Nanosci Nanotechnol. 2017;17(2):990–7.CrossRefPubMed Gong P, Wang Z, Geng J, Tan X. Comparative study on detection and typing of human papillomavirus (HPV) infection with microarray using paraffin-embedded specimens from squamous cell carcinoma and cervical precursor lesions. J Nanosci Nanotechnol. 2017;17(2):990–7.CrossRefPubMed
38.
go back to reference Wang H, Cheng X, Ye J, Xu X, Hong Y, Sui L, You Z, Xie X. Distribution of human papilloma virus genotype prevalence in invasive cervical carcinomas and precancerous lesions in the Yangtze River Delta area, China. BMC Cancer. 2018;18(1):487.CrossRefPubMedPubMedCentral Wang H, Cheng X, Ye J, Xu X, Hong Y, Sui L, You Z, Xie X. Distribution of human papilloma virus genotype prevalence in invasive cervical carcinomas and precancerous lesions in the Yangtze River Delta area, China. BMC Cancer. 2018;18(1):487.CrossRefPubMedPubMedCentral
Metadata
Title
Human papillomavirus infections among women with cervical lesions and cervical cancer in Yueyang, China: a cross-sectional study of 3674 women from 2019 to 2022
Authors
Min Zeng
Xiaoyun Zhang
LiLi He
Xin Liu
Huawen Liu
Rui Deng
Bo Qiu
Fang Liu
Hang Xiao
Quanlv Li
Wen Li
Chongmei Liu
Yangqing Ge
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2023
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-023-02221-w

Other articles of this Issue 1/2023

Virology Journal 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.